Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Kidney Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 25Nivolumab 20atezolizumab 8Magnetic Resonance Spectroscopy 7Ipilimumab 7Specimen Handling 5Paclitaxel 5Fluorodeoxyglucose F18 4Cyclophosphamide 4Carboplatin 4fludarabine 3durvalumab 3avelumab 3Interleukin-2 3Gemcitabine 3Docetaxel 3130-nm albumin-bound paclitaxel 3tislelizumab 2spartalizumab 2regorafenib 2epacadostat 2cabozantinib 2aldesleukin 2Taxes 2Pemetrexed 2FAPI-46 2Cisplatin 2Albumin-Bound Paclitaxel 2zanidatamab 1veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Blood Cell Count × Gastrointestinal × Clear all
NCT07485114 2026-03-20

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Tel-Aviv Sourasky Medical Center

Recruiting
300 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡